financetom
Business
financetom
/
Business
/
Meta Platforms Insider Sold Shares Worth $39,090,791, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Meta Platforms Insider Sold Shares Worth $39,090,791, According to a Recent SEC Filing
Feb 6, 2025 12:37 AM

03:10 AM EST, 02/06/2025 (MT Newswires) -- Mark Zuckerberg, 10% Owner, Director, Chair of Board and Chief Executive Officer, on February 04, 2025, sold 55,589 shares in Meta Platforms ( META ) for $39,090,791. Following the Form 4 filing with the SEC, Zuckerberg has control over a total of 185,021 Class A common shares of the company, with 185,021 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1326801/000095010325001660/xslF345X05/dp224541_4-zuckerberg0204.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US drillers cuts most oil and gas rigs in a month since August - Baker Hughes
US drillers cuts most oil and gas rigs in a month since August - Baker Hughes
May 31, 2024
May 31 (Reuters) - U.S. energy firms this month cut the most oil and natural gas operating since August, even as the rig count remained unchanged this week, energy services firm Baker Hughes ( BKR ) said in its closely followed report on Friday. The oil and gas rig count, an early indicator of future output, held steady at 600...
CAE Ratings Affirmed by S&P
CAE Ratings Affirmed by S&P
May 31, 2024
01:17 PM EDT, 05/31/2024 (MT Newswires) -- S&P Global Ratings on Friday affirmed its ratings on CAE (CAE.TO), including its BBB- issuer credit rating on the company. The rating affirmation comes after CAE reported a re-baselining of its defense business, along with defense impairment charges and contract adjustments related to eight previously identified fixed-price legacy contracts. The stable outlook reflects...
Pfizer Reports Encouraging Long-Term Trial Results of Advanced Lung Cancer Drug
Pfizer Reports Encouraging Long-Term Trial Results of Advanced Lung Cancer Drug
May 31, 2024
01:21 PM EDT, 05/31/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday its Lorbrena drug for an advanced form of lung cancer helped patients live longer without disease progression, based on long-term follow-up results of a late-stage trial. Roughly 60% of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer and treated with Lorbrena were alive without disease...
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise
May 31, 2024
01:21 PM EDT, 05/31/2024 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) was advancing 4% Friday after the drugmaker said a late-stage trial of its candidate, sebetralstat, to treat hereditary angioedema, a swelling disorder, met primary and secondary endpoints. The median time for patients to begin experiencing a reduction in their swelling was 1.61 hours in people who received 300...
Copyright 2023-2026 - www.financetom.com All Rights Reserved